OpportunityTitle: Core Clinical Centers for the Blood and Marrow Transplant Clinical Trials Network (UG1)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Description: This Funding Opportunity Announcement (FOA) invites applications to participate as a Core Clinical Center/Consortia in the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). This collaborative multi-center clinical program promotes the efficient comparison of novel treatment approaches and management strategies for potential benefit of children and adults undergoing hematopoietic stem cell transplantation (HCT), either alone or in combination with novel cell-based therapies. Collaboration among the Core Clinical Centers, the Data Coordinating Center, the NHLBI, the NCI, and other stakeholders will permit multi-center evaluation of new HCT approaches with attention to treatment of malignant and non-malignant blood diseases. During this funding cycle, the BMT CTN will have the flexibility to conduct early phase multi-center HCT trials incorporating novel cell therapies, and to expand the use of promising products from highly selected to more heterogeneous patient populations. The overall goals of the BMT CTN are to improve HCT outcomes, evaluate promising novel cell therapies, and rapidly disseminate study results to improve the scientific basis for the treatment of patients in need of HCT therapy.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;